<DOC>
	<DOCNO>NCT00339664</DOCNO>
	<brief_summary>Cancer patient clinical trial donate various human sample ( e.g. , serum , plasma , blood , urine , feces , bile , saliva ) research purpose . The purpose study conduct analyse exist sample clinical trial perform outside , collaboration , National Cancer Institute .</brief_summary>
	<brief_title>Analyses Human Samples Collected Clinical Trials</brief_title>
	<detailed_description>Various human sample ( e.g. , serum , plasma , whole blood , erythrocytes , urine , feces , bile , and/or saliva ) collect cancer patient enrol approved clinical trial , accordance local protocol . These trial conduct outside institution , collaboration National Cancer Institute ( NCI ) sample sent NCI pharmacological analysis , involve determination parent drug and/or metabolite concentration subsequent pharmacokinetics statistical data analysis . This study aim characterize clinical pharmacokinetic behavior select cancer therapeutic . Future collaborator add via protocol amendment procedure .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>INCLUSION CRITERIA : Any patient enter approved trial cancer therapeutic agent commonly administer patient cancer institution outside intramural NCI eligible inclusion , provide consented pharmacological analysis original consent form . EXCLUSION CRITERIA : None anticipate time .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 9, 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Quantify</keyword>
	<keyword>HPLC</keyword>
	<keyword>LC/MS</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>